

**Freedom of Information Act 2000 – Request Reference FoI/24/022**  
**Biologic Medicines in Dermatology**

**How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:**

For the period 1 October 2023 to 31 December 2023:

- Adalimumab (Humira) – 12
- Adalimumab Biosimilar – 142
- Apremilast – 1
- Bimekizumab – 9
- Brodalumab – 4
- Certolizumab – 10
- Deucravacitinib – 0
- Dimethyl fumarate – 0
- Etanercept (Enbrel) – 0
- Etanercept Biosimilar – 5
- Guselkumab – 14
- Infliximab (Remicade) – 0
- Infliximab Biosimilar – 16
- Ixekizumab – 11
- Risankizumab – 37
- Secukinumab – 35
- Tildrakizumab – 1
- Ustekinumab – 35